Interview with Devaney Baccarin, VP & General Manager, Astellas Pharma…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
Address: Avenida das Nações Unidas, 14.171, Rochaverá Corporate Towers, Torre Marble – 3º andar, Cj. 302,Brazil
Tel: (55 11) 3027-4500
Web: http://www.astellasfarma.com.br/
In July 2009, Astellas Pharma Brazil (AFB) was created due to remarkable growth of the economy in the sector of health care. In April 2010, the Brazilian subsidiary started to promote and distribute products directly that were licensed to other companies.
In Brazil, specifically, Astellas is focused on three areas encompassed in the Astellas Group, Dermatology, Urology and Infectious Diseases. These are the foundations for growth and recognition of Astellas in the Brazilian pharmaceutical market.
Astellas Brazil focuses on becoming the leader in the Brazilian pharmaceutical industry, supports the company’s business philosophy, a VISION 2015, which seeks to become a ‘world leader in the category.’
Omnic®, Omnic OCAS®, Vesicare, Mycamine
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
See our Cookie Privacy Policy Here
